First-line checkpoint inhibitors in PD-L1-positive patients with advanced urothelial carcinoma

被引：1
|
作者：
Tsimafeyeu, Ilya [1 ]
Tjulandin, Sergei [1 ]
机构：
[1] Russian Soc Clin Oncol, Moscow, Russia
来源：
BJU INTERNATIONAL | 2019年 / 123卷 / 04期
关键词：
urothelial carcinoma; atezolizumab; pembrolizumab; cisplatin-ineligible patients; PD-L1; testing; CISPLATIN-INELIGIBLE PATIENTS; SINGLE-ARM; MULTICENTER; ATEZOLIZUMAB; CHEMOTHERAPY;
D O I：
10.1111/bju.14627
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：563 / 565
页数：3
相关论文
共 50 条
  • [1] First-line avelumab for patients with PD-L1-positive metastatic or locally advanced urothelial cancer who are unfit for cisplatin
    Iacovelli, R.
    Ciccarese, C.
    Brunelli, M.
    Battelli, N.
    Buttigliero, C.
    Caserta, C.
    Buti, S.
    Santini, D.
    Carella, C.
    Galli, L.
    Verri, E.
    Ermacora, P.
    Merler, S.
    Masini, C.
    De Vivo, R.
    Milesi, L.
    Spina, F.
    Rizzo, M.
    Sperduti, I.
    Fornarini, G.
    Tortora, G.
    ANNALS OF ONCOLOGY, 2022, 33 (11) : 1179 - 1185
  • [2] First-line PD(L)1 inhibitors for platinum-ineligible advanced urothelial carcinoma (aUC).
    Agarwal, Archana
    Pond, Gregory Russell
    Gupta, Ruby
    Ornstein, Moshe Chaim
    Barata, Pedro C.
    Garcia, Jorge A.
    Drakaki, Alexandra
    Lee, Jae-Lyun
    Kanesvaran, Ravindran
    Bilen, Mehmet Asim
    Lorenzo, Felipe R.
    Grivas, Petros
    Hussain, Syed A.
    Curran, Catherine
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] First-line PD1/PD-L1 inhibitors for platinum-ineligible advanced urothelial carcinoma (UC).
    Agarwal, Archana
    Pond, Gregory Russell
    Drakaki, Alexandra
    Lee, Jae-Lyun
    Bilen, Mehmet Asim
    Di Lorenzo, Giuseppe
    Grivas, Petros
    Ornstein, Moshe Chaim
    Barata, Pedro C.
    Gupta, Shilpa
    Hussain, Syed A.
    Curran, Catherine
    Garcia, Jorge A.
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [4] A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors
    Khaki, Ali Raza
    Li, Ang
    Diamantopoulos, Leonidas N.
    Miller, Natalie J.
    Carril-Ajuria, Lucia
    Castellano, Daniel
    De Kouchkovsky, Ivan
    Koshkin, Vadim
    Park, Joseph
    Alva, Ajjai
    Bilen, Mehmet A.
    Stewart, Tyler
    Santos, Victor
    Agarwal, Neeraj
    Jain, Jayanshu
    Zakharia, Yousef
    Morales-Barrera, Rafael
    Devitt, Michael
    Nelson, Ariel
    Hoimes, Christopher J.
    Shreck, Evan
    Gartrell, Benjamin A.
    Sankin, Alex
    Tripathi, Abhishek
    Zakopoulou, Roubini
    Bamias, Aristotelis
    Rodriguez-Vida, Alejo
    Drakaki, Alexandra
    Liu, Sandy
    Kumar, Vivek
    Lythgoe, Mark P.
    Pinato, David J.
    Murgic, Jure
    Frobe, Ana
    Joshi, Monika
    Velho, Pedro Isaacsson
    Hahn, Noah
    Buznego, Lucia Alonso
    Duran, Ignacio
    Moses, Marcus
    Barata, Pedro
    Galsky, Matthew D.
    Sonpavde, Guru
    Yu, Evan Y.
    Shankaran, Veena
    Lyman, Gary H.
    Grivas, Petros
    EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (03): : 464 - 472
  • [5] Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors
    Pond, Gregory R.
    Agarwal, Archana
    Ornstein, Moshe
    Garcia, Jorge
    Gupta, Ruby
    Grivas, Petros
    Drakaki, Alexandra
    Lee, Jae-Lyun
    Kanesvaran, Ravindran
    Di Lorenzo, Giuseppe
    Verolino, Pasquale
    Barata, Pedro
    Bilen, Mehmet A.
    Hussain, Syed A.
    Curran, Catherine
    Sonpavde, Guru
    CLINICAL GENITOURINARY CANCER, 2021, 19 (05) : 425 - 433
  • [6] Advanced or metastatic Urothelial Carcinoma New First-line Strategy established with PD-L1 Inhibitor
    Freye, Reimund
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (05)
  • [7] Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
    Hui, R.
    Garon, E. B.
    Goldman, J. W.
    Leighl, N. B.
    Hellmann, M. D.
    Patnaik, A.
    Gandhi, L.
    Eder, J. P.
    Ahn, M-J
    Horn, L.
    Felip, E.
    Carcereny, E.
    Rangwala, R.
    Lubiniecki, G. M.
    Zhang, J.
    Emancipator, K.
    Roach, C.
    Rizvi, N. A.
    ANNALS OF ONCOLOGY, 2017, 28 (04) : 874 - 881
  • [8] Cost-effectiveness of analysis serplulimab plus chemotherapy as first-line therapy for PD-L1-positive advanced esophageal squamous cell carcinoma
    Zheng, Hanrui
    Li, Jiafeng
    Wen, Feng
    Su, Na
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [9] First-line immune checkpoint inhibitors for patients with metastatic urothelial carcinoma treated in routine clinical practice
    Naito, Renato
    Izumi, Kouji
    Mizokami, Atsushi
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2020, 9 (03) : 986 - 990
  • [10] First-line treatment options for advanced gastric/gastroesophageal junction cancer patients with PD-L1-positive: a systematic review and meta-analysis
    Fan, Ling
    Lu, Ning
    Zhang, Lingmin
    Zhang, Jie
    Li, Jie
    Cui, Manli
    Zhang, Mingxin
    ANNALS OF MEDICINE AND SURGERY, 2023, 85 (06): : 2875 - 2883
12345